{{unreferenced|date=November 2014}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 398761069
| IUPAC_name = 6-[4-(3,4-Dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
| image = Vesnarinone.svg

<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|international|vesnarinone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 81840-15-5
| ATC_prefix = None
| ATC_suffix =
| ATC_supplemental =
| PubChem = 5663
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 5COW40EV8M
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 17423
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 5461

<!--Chemical data-->
| chemical_formula =  
| C=22 | H=25 | N=3 | O=4 
| molecular_weight = 395.45 g/mol
| smiles = COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = ZVNYJIZDIRKMBF-UHFFFAOYSA-N
}}

'''Vesnarinone''' ([[International Nonproprietary Name|INN]]) is a [[cardiotonic]] agent.
A mixed [[phosphodiesterase 3 inhibitor]] and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of [[heart failure]].

{{Phosphodiesterase inhibitors}}
{{Cardiac stimulants excluding cardiac glycosides}}
{{Piperazines}}

[[Category:Benzamides]]
[[Category:Inotropic agents]]
[[Category:PDE3 inhibitors]]
[[Category:Phenol ethers]]
[[Category:Piperazines]]
[[Category:2-Quinolones]]

{{cardiovascular-drug-stub}}